# A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Source: https://onco.cc/trials/nct05849298/  
OnCo record `nct05849298` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AAA617 in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC is a phase 2 interventional study registered as NCT05849298 by Novartis Pharmaceuticals, with 49 participants enrolled, started 2024-01-03 and due to reach its primary completion in 2026-12-23. Interventions recorded: AAA617, AAA517, Piflufolastat F 18, ARPI and ADT.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05849298
- Phase: 2
- Setting: An International Prospective Open-label, Multi-center, Randomized, Non-comparative Phase II Study of Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) Alone and Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) in Combination With Androgen Receptor Pathway Inhibitors in Patients With PSMA PET Scan Positive Castration-Resistant Prostate Cancer
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT05849298: https://clinicaltrials.gov/study/NCT05849298

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct05849298.json